FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2040534410> ?p ?o ?g. }

• W2040534410 endingPage "CMO.S3920" @default.
• W2040534410 startingPage "CMO.S3920" @default.
• W2040534410 abstract "Background We have previousy reported on a Phase II study of S-1 monotherapy as a first line, combination therapy of S-1 plus cisplatin as a second line, and weekly paclitaxel monotherapy as a third line therapy in patients with advanced gastric carcinomas. The median survival time (MST) of patients over the whole course of treatment was not previously calculated because 12 out of 19 patients had not yet succumbed. Since then, we have calculated the MST for this study and herein report our findings. Patients and Methods Between 2002 and 2005, 19 patients were enrolled in this study. Chemotherapy consisted of either 60 mg/m 2 of S-1 for 4 weeks at 6-week intervals, a combination of 60 mg/m 2 S-1 for 3 weeks and 60 mg/m 2 cisplatin on day 8 at 5-week intervals, or 60 mg/m 2 paclitaxel at days 1, 8, and 15, at 4-week intervals. The regimens were repeated until the occurrence of unacceptable toxicities, disease progression, or patient noncompliance. The primary end point was the overall survival. Results The median survival time was 774 days. The response rates were 33.3% (3/9), 12.5% (1/8), and 0% (0/4) after the first, second, and third line chemotherapies, respectively. The major adverse hematological toxicity was leukopenia, which reached grades 3–4 in all lines of chemotherapy investigated. In addition, the major adverse non-hematological toxicity was anorexia, which reached grade 3–4 in second line chemotherapy, and no deaths were attributable to the adverse effects of the drugs. Conclusion This sequential therapy was an effective treatment for advanced gastric cancer with acceptable toxic side-effects. We considered this therapy to be effective because of the smooth transition to the next regimen." @default.
• W2040534410 created "2016-06-24" @default.
• W2040534410 creator A5007589801 @default.
• W2040534410 creator A5017628553 @default.
• W2040534410 creator A5022193625 @default.
• W2040534410 creator A5049252348 @default.
• W2040534410 creator A5066906544 @default.
• W2040534410 creator A5069995138 @default.
• W2040534410 creator A5074730748 @default.
• W2040534410 creator A5076769300 @default.
• W2040534410 creator A5082957648 @default.
• W2040534410 creator A5084402131 @default.
• W2040534410 date "2010-01-01" @default.
• W2040534410 modified "2023-09-26" @default.
• W2040534410 title "A Phase II Study of S-1 Monotherapy as a First-line Combination Therapy of S-1 plus Cisplatin as a Second-line Therapy, and Weekly Paclitaxel Monotherapy as a Third-line Therapy in Patients with Advanced Gastric Carcinoma: A Second Report" @default.
• W2040534410 cites W162047453 @default.
• W2040534410 cites W1839380746 @default.
• W2040534410 cites W1984445332 @default.
• W2040534410 cites W1989706296 @default.
• W2040534410 cites W2008575122 @default.
• W2040534410 cites W2013537137 @default.
• W2040534410 cites W2027678619 @default.
• W2040534410 cites W2072428999 @default.
• W2040534410 cites W2077902459 @default.
• W2040534410 cites W2171075804 @default.
• W2040534410 cites W2257430737 @default.
• W2040534410 cites W2259246526 @default.
• W2040534410 cites W2395615354 @default.
• W2040534410 cites W2415219757 @default.
• W2040534410 cites W2417704113 @default.
• W2040534410 doi "https://doi.org/10.4137/cmo.s3920" @default.
• W2040534410 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2883242" @default.
• W2040534410 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20567630" @default.
• W2040534410 hasPublicationYear "2010" @default.
• W2040534410 type Work @default.
• W2040534410 sameAs 2040534410 @default.
• W2040534410 citedByCount "3" @default.
• W2040534410 countsByYear W20405344102012 @default.
• W2040534410 countsByYear W20405344102013 @default.
• W2040534410 countsByYear W20405344102018 @default.
• W2040534410 crossrefType "journal-article" @default.
• W2040534410 hasAuthorship W2040534410A5007589801 @default.
• W2040534410 hasAuthorship W2040534410A5017628553 @default.
• W2040534410 hasAuthorship W2040534410A5022193625 @default.
• W2040534410 hasAuthorship W2040534410A5049252348 @default.
• W2040534410 hasAuthorship W2040534410A5066906544 @default.
• W2040534410 hasAuthorship W2040534410A5069995138 @default.
• W2040534410 hasAuthorship W2040534410A5074730748 @default.
• W2040534410 hasAuthorship W2040534410A5076769300 @default.
• W2040534410 hasAuthorship W2040534410A5082957648 @default.
• W2040534410 hasAuthorship W2040534410A5084402131 @default.
• W2040534410 hasBestOaLocation W20405344101 @default.
• W2040534410 hasConcept C126322002 @default.
• W2040534410 hasConcept C141071460 @default.
• W2040534410 hasConcept C143998085 @default.
• W2040534410 hasConcept C197934379 @default.
• W2040534410 hasConcept C203092338 @default.
• W2040534410 hasConcept C2776694085 @default.
• W2040534410 hasConcept C2776999253 @default.
• W2040534410 hasConcept C2777063308 @default.
• W2040534410 hasConcept C2777292972 @default.
• W2040534410 hasConcept C2778239845 @default.
• W2040534410 hasConcept C2778654693 @default.
• W2040534410 hasConcept C2780873365 @default.
• W2040534410 hasConcept C29730261 @default.
• W2040534410 hasConcept C3019864225 @default.
• W2040534410 hasConcept C535046627 @default.
• W2040534410 hasConcept C71924100 @default.
• W2040534410 hasConcept C90924648 @default.
• W2040534410 hasConceptScore W2040534410C126322002 @default.
• W2040534410 hasConceptScore W2040534410C141071460 @default.
• W2040534410 hasConceptScore W2040534410C143998085 @default.
• W2040534410 hasConceptScore W2040534410C197934379 @default.
• W2040534410 hasConceptScore W2040534410C203092338 @default.
• W2040534410 hasConceptScore W2040534410C2776694085 @default.
• W2040534410 hasConceptScore W2040534410C2776999253 @default.
• W2040534410 hasConceptScore W2040534410C2777063308 @default.
• W2040534410 hasConceptScore W2040534410C2777292972 @default.
• W2040534410 hasConceptScore W2040534410C2778239845 @default.
• W2040534410 hasConceptScore W2040534410C2778654693 @default.
• W2040534410 hasConceptScore W2040534410C2780873365 @default.
• W2040534410 hasConceptScore W2040534410C29730261 @default.
• W2040534410 hasConceptScore W2040534410C3019864225 @default.
• W2040534410 hasConceptScore W2040534410C535046627 @default.
• W2040534410 hasConceptScore W2040534410C71924100 @default.
• W2040534410 hasConceptScore W2040534410C90924648 @default.
• W2040534410 hasLocation W20405344101 @default.
• W2040534410 hasLocation W20405344102 @default.
• W2040534410 hasLocation W20405344103 @default.
• W2040534410 hasLocation W20405344104 @default.
• W2040534410 hasOpenAccess W2040534410 @default.
• W2040534410 hasPrimaryLocation W20405344101 @default.
• W2040534410 hasRelatedWork W2036683847 @default.
• W2040534410 hasRelatedWork W2085978374 @default.
• W2040534410 hasRelatedWork W2121856950 @default.
• W2040534410 hasRelatedWork W2260802935 @default.
• W2040534410 hasRelatedWork W2347566873 @default.
• W2040534410 hasRelatedWork W2366392510 @default.

• next